INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

Background Immunotherapies targeting immune checkpoint inhibitors have revolutionized cancer treatment but are limited by incomplete patient responses. Costimulatory agonists like OX40 (CD134), a tumor necrosis factor receptor family member critical for T-cell survival and differentiation, have show...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	William L Redmond, Yoshinobu Koguchi, Melissa J Kasiewicz, Annah S Rolig, Nisha Holay, Bryan Becklund, Anya Polovina, Sae Jeong Ahn, Brendan P Eckelman, Rashi Yadav, Thi Staebler, Noah D Simons, Yaiza Diaz de Durana
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMJ Publishing Group 2025-05-01
סדרה:	Journal for ImmunoTherapy of Cancer
גישה מקוונת:	https://jitc.bmj.com/content/13/5/e011524.full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!